Cite

    Soubrier, M. et al. (2018). Retention rates of adalimumab, etanercept and infliximab as first‐line biotherapy agent for rheumatoid arthritis patients in daily practice ‐ Auvergne experience. International journal of rheumatic diseases. pp. 1924-1932. [Online].